valproic acid has been researched along with Nerve Degeneration in 18 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report here that, while dietary supplementation with high VPA dosage slows down motor neuron death, as assessed by measurement of a specific marker for cholinergic neurons in the spinal cord, it has no significant effect on lifespan." | 5.35 | Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. ( Bonamassa, B; Canistro, D; Contestabile, A; Crochemore, C; Paolini, M; Pena-Altamira, E; Virgili, M, 2009) |
| "Pentylenetetrazol (PTZ)-induced chronic kindling model and lithium-pilocarpine-induced status epilepticus (SE) model were used in this study." | 3.81 | Degeneration and regeneration of GABAergic interneurons in the dentate gyrus of adult mice in experimental models of epilepsy. ( Jiang, W; Wang, Y; Wei, D; Wu, C; Wu, SX; Yang, F, 2015) |
| "An infant with dysmorphic features was born to an epileptic mother who had taken phenytoin and sodium valproate throughout pregnancy." | 3.68 | Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants. ( Hope, PL; Lindenbaum, RH; Squier, W, 1990) |
| "Spinal muscular atrophy is a devastating disease that is characterized by degeneration and death of a specific subclass of motor neurons in the anterior horn of the spinal cord." | 1.43 | Neuron-specific knock-down of SMN1 causes neuron degeneration and death through an apoptotic mechanism. ( Battaglia, GS; Bazzicalupo, P; Castro, S; Chaplin, JC; Di Schiavi, E; Donato, A; Esposito, A; Gallotta, I; Hilliard, MA; Mazzarella, N; Zampi, G, 2016) |
| " We report here that, while dietary supplementation with high VPA dosage slows down motor neuron death, as assessed by measurement of a specific marker for cholinergic neurons in the spinal cord, it has no significant effect on lifespan." | 1.35 | Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. ( Bonamassa, B; Canistro, D; Contestabile, A; Crochemore, C; Paolini, M; Pena-Altamira, E; Virgili, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kautu, BB | 1 |
| Carrasquilla, A | 1 |
| Hicks, ML | 1 |
| Caldwell, KA | 1 |
| Caldwell, GA | 1 |
| Croce, N | 1 |
| Bernardini, S | 1 |
| Caltagirone, C | 1 |
| Angelucci, F | 1 |
| Wei, D | 1 |
| Yang, F | 2 |
| Wang, Y | 1 |
| Wu, C | 1 |
| Wu, SX | 1 |
| Jiang, W | 1 |
| Gallotta, I | 1 |
| Mazzarella, N | 1 |
| Donato, A | 1 |
| Esposito, A | 1 |
| Chaplin, JC | 1 |
| Castro, S | 1 |
| Zampi, G | 1 |
| Battaglia, GS | 1 |
| Hilliard, MA | 1 |
| Bazzicalupo, P | 1 |
| Di Schiavi, E | 1 |
| Crochemore, C | 1 |
| Virgili, M | 1 |
| Bonamassa, B | 1 |
| Canistro, D | 1 |
| Pena-Altamira, E | 1 |
| Paolini, M | 1 |
| Contestabile, A | 1 |
| Yamauchi, J | 1 |
| Torii, T | 1 |
| Kusakawa, S | 1 |
| Sanbe, A | 1 |
| Nakamura, K | 1 |
| Takashima, S | 1 |
| Hamasaki, H | 1 |
| Kawaguchi, S | 1 |
| Miyamoto, Y | 1 |
| Tanoue, A | 1 |
| Kidd, SK | 1 |
| Schneider, JS | 1 |
| Penas, C | 1 |
| Verdú, E | 1 |
| Asensio-Pinilla, E | 1 |
| Guzmán-Lenis, MS | 1 |
| Herrando-Grabulosa, M | 1 |
| Navarro, X | 1 |
| Casas, C | 1 |
| Wang, C | 1 |
| Luan, Z | 1 |
| Yang, Y | 1 |
| Wang, Z | 1 |
| Cui, Y | 1 |
| Gu, G | 1 |
| Bown, CD | 1 |
| Wang, JF | 2 |
| Young, LT | 2 |
| Angehagen, M | 1 |
| Ben-Menachem, E | 1 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Brandt, C | 1 |
| Gastens, AM | 1 |
| Sun, Mz | 1 |
| Hausknecht, M | 1 |
| Löscher, W | 1 |
| Tsai, LK | 1 |
| Tsai, MS | 1 |
| Lin, TB | 1 |
| Hwu, WL | 1 |
| Li, H | 1 |
| Cui, J | 1 |
| Shao, L | 1 |
| Sinn, DI | 1 |
| Kim, SJ | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Lee, ST | 1 |
| Song, EC | 1 |
| Kim, JM | 1 |
| Park, DK | 1 |
| Kun Lee, S | 1 |
| Kim, M | 1 |
| Roh, JK | 1 |
| Sobaniec-Lotowska, M | 1 |
| Sobaniec, W | 1 |
| Schwarcz, R | 1 |
| Bennett, JP | 1 |
| Coyle, JT | 1 |
| Squier, W | 1 |
| Hope, PL | 1 |
| Lindenbaum, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849] | Phase 2 | 128 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) |
|---|---|
| Cherry Syrup | -2 |
| Valproic Acid | -2 |
The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cherry Syrup | 37 |
| Valproic Acid | 36 |
The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| BPI Average Pain Score | BPI interference question sum | |
| Cherry Syrup | -2 | -15 |
| Valproic Acid | -1 | -7 |
The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| DVPRS numeric pain | DVPRS Supplemental Question Sum | |
| Cherry Syrup | -2 | -9 |
| Valproic Acid | 0 | -4.5 |
The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | morphine milligram equivalents (Median) | |
|---|---|---|
| Postoperative hours 0-24 | Postoperative hours 24-48 | |
| Cherry Syrup | 59 | 49 |
| Valproic Acid | 33 | 45 |
The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Residual limb pain | Phantom limb | |
| Cherry Syrup | 29 | 22 |
| Valproic Acid | 31 | 26 |
The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | score on a scale (Median) | |
|---|---|---|
| Post-op hours 0-24 | Post-op hours 24-48 | |
| Cherry Syrup | 0 | 0 |
| Valproic Acid | 0 | 0 |
18 other studies available for valproic acid and Nerve Degeneration
| Article | Year |
|---|---|
Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.
Topics: alpha-Synuclein; Animals; Anticonvulsants; Caenorhabditis elegans; Caenorhabditis elegans Proteins; | 2013 |
Lithium/Valproic acid combination and L-glutamate induce similar pattern of changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells.
Topics: Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation; Glu | 2014 |
Degeneration and regeneration of GABAergic interneurons in the dentate gyrus of adult mice in experimental models of epilepsy.
Topics: Animals; Chronic Disease; Dentate Gyrus; Epilepsy; GABAergic Neurons; Glutamate Decarboxylase; Green | 2015 |
Neuron-specific knock-down of SMN1 causes neuron degeneration and death through an apoptotic mechanism.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Disease Models, Animal; Gene Knockdo | 2016 |
Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animal Feed; Animals; Antineoplastic Agents; Ch | 2009 |
The mood stabilizer valproic acid improves defective neurite formation caused by Charcot-Marie-Tooth disease-associated mutant Rab7 through the JNK signaling pathway.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Charcot-Marie-Tooth Disease; Humans; JNK Mitogen-Activat | 2010 |
Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition.
Topics: 1-Methyl-4-phenylpyridinium; Acetylation; Analysis of Variance; Animals; Apoptosis; Butyric Acid; Ce | 2010 |
Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury.
Topics: Animals; Axons; Cell Count; Cells, Cultured; Dose-Response Relationship, Drug; Endoplasmic Reticulum | 2011 |
Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-α from activated astrocytes.
Topics: Aborted Fetus; Anticonvulsants; Apoptosis; Astrocytes; Cell Differentiation; Cells, Cultured; Hippoc | 2011 |
Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cell Survival; Cells, Cultured; Cytoplas | 2003 |
Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Calcium; Calcium Signaling; Cell Membrane; C | 2003 |
Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Body Weight; Cell Death; Disease Models, Animal; Dose-Re | 2006 |
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy.
Topics: Animals; Cell Death; Cell Survival; Cyclic AMP Response Element-Binding Protein; Disease Models, Ani | 2006 |
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate.
Topics: Animals; Antimanic Agents; Brain; Carbamazepine; Cell Death; Cell Line, Tumor; Cells, Cultured; Cere | 2007 |
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Death; Cerebral Hemorrhage; Chemotaxis, Leukocyte; Dise | 2007 |
Effect of chronic administration of sodium valproate on the morphology of the rat brain hemispheres.
Topics: Animals; Brain; Capillary Permeability; Chemical and Drug Induced Liver Injury; Culture Techniques; | 1993 |
Inhibitors of GABA metabolism: implications for Huntington's disease.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Aminocaproic Acid; Animals; Caudate Nucleus; | 1977 |
Neocerebellar hypoplasia in a neonate following intra-uterine exposure to anticonvulsants.
Topics: Abnormalities, Drug-Induced; Cerebellum; Drug Therapy, Combination; Epilepsy; Female; Humans; Nerve | 1990 |